Breakthrough in Precision Cancer Therapy: Liver-Sparing in Early Studies
Lehi, Utah — CancerVax, Inc., a pre-clinical biotechnology company, announced today that recent in-vitro studies demonstrate a significant reduction in liver toxicity for its universal cancer treatment platform. The findings address a long-standing challenge in oncology: protecting healthy liver tissue while delivering effective cancer-killing therapy. If validated in later stages, the technology could redefine how clinicians approach a wide range of cancers by improving safety profiles and expanding treatment options.
How CancerVax’s Platform Works: Detect, Mark, and Kill
The CancerVax platform relies on a two-step cell-targeting mechanism powered by sophisticated AI and machine-learning algorithms. First, specially engineered nanoparticles bind to surface proteins highly associated with the target cancer cells, a process the company labels as Marker1 detection. Once inside the cancer cell, a proprietary “Smart mRNA” payload is released only in the presence of cancer-specific genetic signatures, referred to as Marker2. This dual-marker strategy aims to de-activate healthy tissues and concentrate immune system activity on malignant cells.
Reducing Liver Exposure: A Key Safety Milestone
The liver is the primary organ for drug metabolism, and many cancer therapies inadvertently affect healthy liver tissue. In their latest studies, CancerVax researchers found that their Smart mRNA sequences designed for pancreatic and liver cancers were dramatically deactivated in healthy human liver cells. In practical terms, the nanoparticles now show a reduced likelihood of mistaking normal liver tissue for cancerous targets, potentially lowering the risk of liver damage and liver failure often seen with conventional therapies.
What the Scientists Say
Dr. George Katibah, Chief Scientific Officer, described the results as striking. “These results are remarkable. We’re transitioning from artificial cell models to human-derived healthy liver cells, and the data are highly encouraging. This gives us confidence that our targeted therapy will reduce potential harm to the liver and other major organs.”
Dr. Adam Grant, Principal Scientist, emphasized the platform’s universal appeal. “Our approach uses proprietary AI to mine cancer genomics databases to discover universal biomarkers. This could enable off-the-shelf injections that address multiple cancer types, potentially lowering costs and expanding access.”
The Path Forward: From In-Vitro to In-Vivo and Beyond
While the new findings focus on in-vitro work, CancerVax framed the results as a crucial safety milestone on the path toward pre-clinical development and eventual clinical trials. The company has positioned its platform as a customizable injection designed to detect, mark, and kill cancer cells while preserving healthy tissue. If the therapy proves effective across additional models and patient populations, it could significantly shorten development timelines and reduce the burden of cancer treatment costs.
Universal Cancer Treatment: One Platform, Many Indications
A core advantage highlighted by CancerVax leadership is the potential for a single technology to treat multiple cancer indications. By leveraging AI to identify Marker1 and Marker2 combinations valid across tumor types, the team envisions a scalable pipeline that could span numerous cancers without the need for fully bespoke therapies for each patient. This approach could transform a landscape where the number of cancer types (~200) vastly outnumbers the global population (~8 billion), by enabling more efficient drug development and broader patient access.
About CancerVax
CancerVax is pursuing a universal cancer treatment platform that aims to be customizable as an injection, designed to activate the body’s immune response against cancer while sparing healthy tissues. The company invites interested readers to learn more through its explainer video and website.
Forward-Looking Statements
The press release contains forward-looking statements subject to risks and uncertainties. The company cautions that actual results may differ materially from those described and undertakes no obligation to publicly update any forward-looking statements.
Press Contact
CancerVax, Inc. | Tel: (805) 356-1810 | communications@CancerVax.com
